The role of dopamine D3, 5-HT2A and 5-HT2C receptor variants as pharmacogenetic determinants in tardive dyskinesia in African-Caribbean patients under chronic antipsychotic treatment: Cura §ao extrapyramidal syndromes study IX

Journal of Psychopharmacology

Volumn 23, Issue 6, 2009, Pages 652-659

  Wilffert, B ^a,b   Al Hadithy, A F Y ^a,b   Sing, V J ^c   Matroos, G ^b   Hoek, H W ^d   Van Os, J ^e   Bruggeman, R ^d   Brouwers, J R B J ^a,b   Van Harten, P N ^b,d,f  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b Department of Clinical Pharmacy of Zorggroep Noorderbreedte and de Tjongerschans ^*  (Netherlands Antilles)

^c PARNASSIA PSYCHIATRIC INSTITUTE   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e MAASTRICHT UNIVERSITY   (Netherlands)

^f Symfora Group Psychiatric Center   (Netherlands)

Author keywords

5HT2A and 5HT2C receptors; African Caribbean; Antipsychotics; D3 receptor; Pharmacogenetics; Polymorphisms; Tardive dyskinesia

Indexed keywords

CHLORPROMAZINE; DOPAMINE 3 RECEPTOR; RISPERIDONE; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR;

ADULT; AFRICAN CARIBBEAN; AGE DISTRIBUTION; AMINO ACID SUBSTITUTION; ARTICLE; CLINICAL FEATURE; DNA POLYMORPHISM; DRUG RESPONSE; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOTE; HUMAN; INVOLUNTARY MOVEMENT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; RECEPTOR GENE; TARDIVE DYSKINESIA; TREATMENT OUTCOME;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; AGING; ALLELES; ANTIPSYCHOTIC AGENTS; DNA; DYSKINESIA, DRUG-INDUCED; FEMALE; GENE FREQUENCY; GENETIC VARIATION; GENOTYPE; HETEROZYGOTE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS ANTILLES; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTOR, SEROTONIN, 5-HT2C; RECEPTORS, DOPAMINE D3;

EID: 67651166877     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108091594     Document Type: Article

References (46)

1. American Psychiatric Association Task force on tardive dyskinesia (1992) Tardive Dyskinesia: A task Force Report of the American Psychiatric Association. Washington DC: APA.
2. Bakker PR van Harten PN van Os J (2006) Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr Res 83: 185-192.
3. Basile VS Masellis M Potkin SG Kennedy JL (2002) Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum Mol Genet 11: 2517-2530.
4. Basile VS Ozdemir V Masellis M Meltzer HY Lieberman JA Potkin SG (2001) Lack of association between serotonin-2A receptor gene (HTR2A) polymorphisms and tardive dyskinesia in schizophrenia. Mol Psychiatry 6: 230-234.
5. Chong SA Tan EC Tan CH Mythily, Chan, YH (2003) Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am J Med Genet B Neuropsychiatr Genet 116: 51-54.
6. Coffey GL Botts SR de, LJ (2005) High vulnerability to acute dystonic reactions: a case of antipsychotic exposure and uncontrolled seizure activity. Prog Neuropsychopharmacol Biol Psychiatry 29: 770-774.
7. Davis JM (1976) Comparative doses and costs of antipsychotic medication. Arch Gen Psychiatry 33: 858-861.
8. Eastham JH Lacro JP Jeste DV (1996) Ethnicity and movement disorders. Mt Sinai J Med 63: 314-319.
9. Ebstein RP Segman R Benjamin J Osher Y Nemanov L Belmaker RH (1997) 5-HT2C (HTR2C) serotonin receptor gene polymorphism associated with the human personality trait of reward dependence: interaction with dopamine D4 receptor (D4DR) and dopamine D3 receptor (D3DR) polymorphisms. Am J Med Genet 74: 65-72.
10. Eichhammer P Albus M Borrmann-Hassenbach M Schoeler A Putzhammer A Frick U (2000) Association of dopamine D3-receptor gene variants with neuroleptic induced akathisia in schizophrenic patients: a generalization of Steen's study on DRD3 and tardive dyskinesia. Am J Med Genet 96: 187-191.
11. Ellingrod VL Lund BC Miller D Fleming F Perry P Holman TL (2003) 5-HT2A seceptor promoter polymorphism, ĝ̂'1438G/A and negative symptom response to olanzapine in schizophrenia. Psychopharmacol Bull 37: 109-112.
12. Frackiewicz EJ Sramek JJ Herrera JM Kurtz NM Cutler NR (1997) Ethnicity and antipsychotic response. Ann Pharmacother 31: 1360-1369.
13. Gerlach J (1999) The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 60 (Suppl. 23). 20-24.
14. Gerlach J (2002) Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psychiatry 14: 47-57.
15. Glazer WM (2000) Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 61 (Suppl. 4). 15-20.
16. Herken H Erdal ME Boke O Savas HA (2003) Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene. Eur Psychiatry 18: 77-81.
17. Jeste DV Caligiuri MP (1993) Tardive dyskinesia. Schizophr Bull 19: 303-315.
18. Kane JM Woerner M Lieberman J (1988) Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 8: 52S - 56S.
19. Kouzmenko AP Scaffidi A Pereira AM Hayes WL Copolov DL Dean B (1999) No correlation between A (ĝ̂'1438). polymorphism in 5-HT2A receptor gene promoter and the density of frontal cortical 5-HT2A receptors in schizophrenia. Hum Hered 49: 103-105.
20. Lannfelt L Sokoloff P Martres MP Pilon C Giros B Jonsson E (1992) Amino acid substitution in the dopamine D3 receptor as a useful polymorphism for investigating psychiatric disorders. Psychiatr Genet 2: 249-256.
21. Lattuada E Cavallaro R Serretti A Lorenzi C Smeraldi E (2004) Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int J Neuropsychopharmacol 7: 489-493.
22. Lerer B Segman RH Fangerau H Daly AK Basile VS Cavallaro R (2002) Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology 27: 105-119.
23. Lerer B Segman RH Tan EC Basile VS Cavallaro R Aschauer HN (2005) Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int J Neuropsychopharmacol 8: 411-425.
24. Liao DL Yeh YC Chen HM Chen H Hong CJ Tsai SJ (2001) Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 44: 95-98.
25. Malik P Andersen MB Peacock L (2004) The effects of dopamine D3 agonists and antagonists in a nonhuman primate model of tardive dyskinesia. Pharmacol Biochem Behav 78: 805-810.
26. Mihara K Kondo T Higuchi H Takahashi H Yoshida K Shimizu T (2002) Tardive dystonia and genetic polymorphisms of cytochrome P4502D6 and dopamine D2 and D3 receptors: a preliminary finding. Am J Med Genet 114: 693-695.
27. Miller SA Dykes DD Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.
28. Morgenstern H Glazer WM (1993) Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 50: 723-733.
29. Muller DJ Schulze TG Knapp M Held T Krauss H Weber T (2001) Familial occurrence of tardive dyskinesia. Acta Psychiatr Scand 104: 375-379.
30. Page WF (1997) The Dutch Triangle: The Netherlands and the Atlantic Slave Trade, 1621-1664, First ed. New York: Garland.
31. Reynolds GP Templeman LA Zhang ZJ (2005) The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Prog Neuropsychopharmacol Biol Psychiatry 29: 1021-1028.
32. Rosengarten H Schweitzer JW Friedhoff AJ (1994) Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol Biochem Behav 49: 663-667.
33. Segman RH Heresco-Levy U Finkel B Goltser T Shalem R Schlafman M (2001) Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol Psychiatry 6: 225-229.
34. Segman RH Heresco-Levy U Finkel B Inbar R Neeman T Schlafman M (2000) Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl) 152: 408-413.
35. Spurlock G Heils A Holmans P Williams J D'Souza UM Cardno A (1998) A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 3: 42-49.
36. Strejilevich SA Palatnik A Avila R Bustin J Cassone J Figueroa S (2005) Lack of extrapyramidal side effects predicts quality of life in outpatients treated with clozapine or with typical antipsychotics. Psychiatry Res 133: 277-280.
37. Tan EC Chong SA Mahendran R Dong F Tan CH (2001) Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biol Psychiatry 50: 144-147.
38. van Harten PN Hoek HW Matroos GE Koeter M Kahn RS (1998) Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curacao Extrapyramidal Syndromes Study III. Am J Psychiatry 155: 565-567.
39. van Harten PN Matroos GE Hoek HW Kahn RS (1996) The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curacao Extrapyramidal Syndromes Study: I. Schizophr Res 19: 195-203.
40. Warren JT Peacock ML Rodriguez LC Fink JK (1993) An MspI polymorphism in the hyman serotonin receptor gene (HTR2). detection by DGGE and RFLP analysis. Hum Mol Genet 2: 338.
41. Weinhold P Wegner JT Kane JM (1981) Familial occurrence of tardive dyskinesia. J Clin Psychiatry 42: 165-166.
42. Werge T Elbaek Z Andersen MB Lundbaek JA Rasmussen HB (2003) Cebus apella, a nonhuman primate highly susceptible to neuroleptic side effects, carries the GLY9 dopamine receptor D3 associated with tardive dyskinesia in humans. Pharmacogenomics J 3: 97-100.
43. Wonodi I Adami HM Cassady SL Sherr JD Avila MT Thaker GK (2004) Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J Clin Psychopharmacol 24: 592-598.
44. Yassa R Ananth J (1981) Familial tardive dyskinesia. Am J Psychiatry 138: 1618-1619.
45. Youssef H Lyster G Youssef F (1989) Familial psychosis and vulnerability to tardive dyskinesia. Int Clin Psychopharmacol 4: 323-328.
46. Zhang ZJ Zhang XB Sha WW Zhang XB Reynolds GP (2002) Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol Psychiatry 7: 670-671.